Genetic Overlap Between Psychoactive Substance Use and Cancer: Findings from an Extensive Genome-Wide Cross-Trait Analysis - Top-Institutions - MDSpire

Genetic Overlap Between Psychoactive Substance Use and Cancer: Findings from an Extensive Genome-Wide Cross-Trait Analysis

  • By

  • Jiahang Song

  • Pengzhu Li

  • Martin Canis

  • Kristian Unger

  • Nikolaus Alexander Haas

  • Olivier Gires

  • February 5, 2026

  • 0 min

Share

Top Institutions in Cardiology

Brief introduction explaining scope and methodology.

  • #1

    National Cancer Institute (NCI)
    National Cancer Institute (NCI)

    Bethesda, MD

    Key Differentiators

    • Cancer Genomics
    • Epidemiology
    • Addiction Research

  • #2

    Broad Institute of MIT and Harvard
    Broad Institute of MIT and Harvard

    Cambridge, MA

    Key Differentiators

    • Genomics
    • Computational Biology
    • Psychiatric Genetics

  • #3

    Johns Hopkins University School of Medicine
    Johns Hopkins University School of Medicine

    Baltimore, MD

    Key Differentiators

    • Oncology
    • Addiction Medicine
    • Genetic Epidemiology

  • #4

    University of California, San Francisco (UCSF)
    University of California, San Francisco (UCSF)

    San Francisco, CA

    Key Differentiators

    • Cancer Biology
    • Addiction Psychiatry
    • Genomics

  • #5

    University of Pennsylvania Perelman School of Medicine
    University of Pennsylvania Perelman School of Medicine

    Philadelphia, PA

    Key Differentiators

    • Genetics
    • Oncology
    • Addiction Research

Original Source(s)

Genetic Overlap Between Psychoactive Substance Use and Cancer: Findings from an Extensive Genome-Wide Cross-Trait Analysis

  • by Jiahang Song, Pengzhu Li, Martin Canis, Kristian Unger, Nikolaus Alexander Haas, Olivier Gires

  • February 5, 2026

Related Content

Ionizing Radiation Promotes Expansion of a p90RSK-Activated Subset of Patrolling Monocytes: Influence of Colchicine

Comprehensive safety analysis of the clinical spectrum of adverse events associated with immune checkpoint inhibitors based on FAERS

Safety and activity of RO7300490, a bispecific CD40 agonist targeted to fibroblast activation protein, in patients with advanced solid tumors: a single-arm, multicenter, first-in-human, phase 1 trial